A useful distinction here is between a promising signal and a practice-ready change. The studies described suggest some cancers may respond to less immunotherapy than the current label allows, but the evidence so far is still early, mixed and often based on small groups. That matters because in oncology, a treatment can look encouraging in one setting without being reliably interchangeable with standard dosing across cancers, stages or patient populations.
Another key issue is what the trials do and do not compare. In some settings, lower-dose treatment was tested against no immunotherapy, not against the approved regimen. That means the results may support the idea that โsome drug is better than noneโ when access is limited, but they do not prove that reduced dosing matches full dosing. For patients and clinicians, that difference is crucial when weighing convenience, cost and the risk of undertreatment.
The practical appeal is clear, especially where price blocks access. Fewer infusions or shorter courses could reduce travel burden, clinic time and financial toxicity, all of which can affect adherence and real-world benefit. But shorter treatment also raises a trade-off: if a drug is stopped too early, the gain in access may come with less durable control in some patients. That uncertainty is why the strongest takeaway is not โless is always enough,โ but that dose and duration deserve careful re-testing with outcomes that matter most, including survival and relapse.
For readers, the broader lesson is that cancer treatment evidence is often context-specific. A result from one tumor type, one population or one health system may not translate cleanly elsewhere. The next step is not broad dose-cutting on instinct, but better-designed trials that identify when lower exposure preserves benefit, when it does not, and which patients are most likely to be helped by a cost-saving approach.
Fighting Cancer for Less
Immunotherapy drugs such as Merck & Co.โs Keytruda and Opdivo from Bristol Myers Squibb Co. have transformed cancer treatment in recent years, boosting survival rates forย numerous types of tumors.ย They also cost more than $200,000 a year in the US.
Lately, researchers in Europe, India and elsewhere have been exploring using significantly less medicine. One trial in India found that ultra-low doses of immunotherapy boosted survival forย head and neck cancer patients, while a recent small study in the US hinted that reduced quantities also may work in advanced skin cancer. Trialsย of other dose-sparing strategies are underway in Europe.
A few days ago, additionalย positive data onย lower doses was presentedย at the European Society for Medical Oncology in Germany. In a 157-person trial done in India, doctors found that using less than a tenth of the approved pre-surgicalย dose of Keytruda could substantially boost theย number ofย triple negative breast cancer patients that were totally free of cancer afterย an operation, as compared with not having Keytruda at all.ย
Meanwhile, a second trial at the meeting fromย researchers in the Netherlands looked at stopping drugsย like Keytruda or Opdivo after roughlyย six months inย melanoma patients whose tumors had shrunk substantially.ย Theyโre typically treated for at least 24 months. It found that a large majority were alive and still responding after two years, suggesting the curtailed therapy may offer benefits such as fewer treatment visitsย for patients wanting to try it.
The trials are small and donโt prove that shorter regimens are as good as standard doses. Nonetheless, academic researchers sayย the results addย to aย mosaic of findings that lower doses or shorter courses may still be highly potent. Thatโs good news for patients in places where access to the pricey drugs is limited.
โItโs just adding another piece of evidence into the increasing wall of data to support the whole concept,โ saysย Daniel Goldstein, an oncologist at Rabin Medical Center in Israel, who has advocated forย using lower โweight-basedโ dosing for Keytruda.
Merck says it performed extensive clinical studies to determine the optimal dose and duration for Keytruda, the biggest selling drug in the world.ย New approaches that havenโt been studied as carefullyย โshould be interpreted with caution and may potentially compromise the therapeutic effect,โ it says in response to questions about the impact of lower doses.
Bristolโs also made the point thatย some studies, including one in lung cancer, show thatย curtailing immunotherapy treatment can lead to worse outcomes. The company saysย itโs difficult to draw conclusions about the melanoma trial due to its limitations. The study didnโt have a control group.
Still, some experts are calling for action.
โWe urgently need to revisit the dose,โ of immunotherapy drugs, saysย Atul Batra, an oncologist and trial investigator at Original Postw9s4vfxGhQuFuAGu6jCr4MZX3lwoTDL/14" target="_blank" rel="noopener" shape="rect">All India Institute ofย Medical Sciences, from the ESMO meeting. In an interview, he compared the drugs to traffic cops that direct the immune system, saying patients need just enough toย trigger it to fight the cancer.
In Batraโsย ESMO trial, 53.8% of women with triple negative breast cancer who received low dose Keytruda plus chemotherapy before surgery were free of cancer after it, a so-called pathologic complete response. That compared toย just 40.5% of those who wereย cancer-free in a control group who got chemotherapy alone.ย
The studyย didnโt directly compare low dose to standard dose Keytruda, and the Indian researchers donโt yet haveย survival data. Countries that can afford the full dose are unlikely to cutย it without much more data.
Lower doses could help more people access careย in countries like India, where manyย canโt afford immunotherapy today. When I went to India for a story on this subject in May, I met several patients who benefitedย from reduced dose immunotherapy for various tumors. None could affordย the standard dose.
โThe benefits could be hugeโ if the lower-dose breast cancer regimen is widely adopted in low- and middle-income countries, Batra said. In India alone,ย some 40,000 women a year get this type of early stage breast cancer, he estimated. Only a tiny fraction can afford the full dose now, he said. โย Robert Langrethย and Ashleigh Furlong
| |
|
Enjoyed this article? Sign up for our newsletter to receive regular insights and stay connected.